DRICORT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DRICORT (DRICORT).
Corticosteroid with predominant glucocorticoid activity; binds to glucocorticoid receptors, modulating gene expression and suppressing inflammatory mediators (e.g., prostaglandins, leukotrienes) and immune cell function.
| Metabolism | Primarily hepatic metabolism via CYP3A4; undergoes reduction, conjugation, and hydrolysis. |
| Excretion | Primarily renal (80-85% as unchanged drug and metabolites), with 15-20% excreted in feces via biliary elimination. |
| Half-life | Terminal elimination half-life is 10-12 hours in adults with normal renal function, allowing twice-daily dosing. |
| Protein binding | 90-95%, primarily bound to albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | 1.2-1.5 L/kg, indicating extensive tissue distribution with high intracellular penetration. |
| Bioavailability | Oral: 60-70% (due to hepatic first-pass metabolism); Intramuscular: 80-90%; Bioavailability by other routes not established. |
| Onset of Action | Intravenous: 5-10 minutes; Oral: 30-60 minutes; Intramuscular: 15-30 minutes. |
| Duration of Action | 12-24 hours, with clinical effects persisting throughout the dosing interval. |
| Molecular Weight | 392.47 |
DRICORT (dexamethasone) typical adult dose: 0.5-9 mg/day orally in divided doses every 6-12 hours, or 0.5-24 mg IV/IM once or divided. Anti-inflammatory: 0.75-9 mg/day PO/IV in 2-4 divided doses. Severe conditions: up to 16 mg/day in divided doses. Short-term high-dose: up to 40-100 mg IV push for specific indications.
| Dosage form | LOTION |
| Renal impairment | No dose adjustment required in renal impairment. Dexamethasone is primarily hepatically metabolized with less than 2% renal excretion. |
| Liver impairment | Child-Pugh A/B: No adjustment. Child-Pugh C: Consider dose reduction (e.g., reduce by 50%) due to decreased clearance; monitor for adverse effects. |
| Pediatric use | Neonates/Infants: 0.05-0.15 mg/kg/day PO/IV divided q6-12h. Children: 0.1-0.5 mg/kg/day PO/IV divided q6-12h (max 16 mg/day). Anti-inflammatory/immunosuppressive: 0.08-0.3 mg/kg/day or 2.5-10 mg/m²/day divided q6-12h. |
| Geriatric use | Elderly patients may require lower doses due to decreased hepatic function and increased susceptibility to adverse effects (e.g., hyperglycemia, osteoporosis). Start at lower end of dosing range and titrate carefully based on response and tolerability. Monitor for fluid retention and electrolyte imbalances. |
| 1st trimester | Avoid; risk of cleft palate and other malformations with systemic corticosteroids in first trimester. Use only if clearly needed. |
| 2nd trimester | Use with caution; monitor fetal growth due to risk of growth restriction. Not recommended for prolonged use. |
| 3rd trimester | Use with caution; risk of neonatal adrenal suppression if prolonged use. Avoid in preeclampsia. |
Clinical note
Comprehensive clinical and safety monograph for DRICORT (DRICORT).
| Placental transfer | Betamethasone crosses the placenta extensively (70-90% of maternal concentration reaches fetus). Used for fetal lung maturation. |
| Breastfeeding | Systemic corticosteroids like DRICORT (betamethasone) are excreted in breast milk in low amounts; however, high doses may affect infant growth or adrenal function. Use lowest effective dose for shortest duration. Monitor infant for signs of adrenal suppression. |
■ FDA Black Box Warning
No FDA black box warnings.
| Serious Effects |
Systemic fungal infectionHypersensitivity to betamethasone or any excipientIntrathecal administrationAdministration of live or live-attenuated vaccines with immunosuppressive dosesIdiopathic thrombocytopenic purpura (for IM use)
| Precautions | Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Local and systemic infections, Skin atrophy and striae, Perioral dermatitis, Allergic contact dermatitis, Use in children may lead to growth retardation |
| Food/Dietary | Avoid grapefruit and grapefruit juice due to potential CYP3A4 inhibition increasing drug levels; limit sodium intake to reduce fluid retention. |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | DRICORT (a corticosteroid) is associated with increased risk of cleft lip/palate with first trimester exposure. Second/third trimester use may cause fetal adrenal suppression, intrauterine growth restriction, and oligohydramnios. Risk-benefit must be assessed. |
| Fetal Monitoring | Monitor maternal blood glucose, blood pressure, and signs of infection. Fetal ultrasound for growth restriction, and neonatal monitoring for adrenal insufficiency after delivery. |
| Fertility Effects | High doses may disrupt menstrual cycle and ovulation, potentially reducing fertility. Effects are reversible with dose reduction. |
| Clinical Pearls | For acute asthma exacerbation, administer early in the emergency department; taper dose over 1-2 weeks to avoid adrenal insufficiency; monitor for hyperglycemia in diabetic patients. |
| Patient Advice | Do not stop taking this medication abruptly; follow the tapering schedule prescribed by your doctor. · Avoid exposure to infections; contact your doctor if you develop fever or other signs of infection. · Take with food or milk to reduce gastrointestinal upset. · Notify your doctor if you experience unusual weight gain, swelling, or mood changes. |